La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Nxera Pharma Gestione

Gestione criteri di controllo 2/4

Nxera Pharma's Il CEO è Chris Cargill, nominato in Mar2022, ha un mandato di 2.42 anni. possiede direttamente 0.046% delle azioni della società, per un valore di ¥ 69.41M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 5.4 anni.

Informazioni chiave

Chris Cargill

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	2.4yrs
Proprietà del CEO	0.05%
Durata media del management	2.4yrs
Durata media del Consiglio di amministrazione	5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Jun 26

Is Nxera Pharma (TSE:4565) A Risky Investment?

Apr 06

Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Mar 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chris Cargill rispetto agli utili di Nxera Pharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-JP¥10b
Mar 31 2024	n/a	n/a	-JP¥9b
Dec 31 2023	n/a	n/a	-JP¥7b
Sep 30 2023	n/a	n/a	-JP¥3b
Jun 30 2023	n/a	n/a	JP¥2b
Mar 31 2023	n/a	n/a	JP¥1b
Dec 31 2022	JP¥292m	JP¥88m	JP¥382m
Sep 30 2022	n/a	n/a	-JP¥383m
Jun 30 2022	n/a	n/a	-JP¥224m
Mar 31 2022	n/a	n/a	JP¥100m
Dec 31 2021	JP¥231m	JP¥65m	JP¥1b
Sep 30 2021	n/a	n/a	JP¥1b
Jun 30 2021	n/a	n/a	JP¥1b
Mar 31 2021	n/a	n/a	JP¥1b
Dec 31 2020	JP¥157m	JP¥53m	JP¥1b
Sep 30 2020	n/a	n/a	-JP¥2b
Jun 30 2020	n/a	n/a	-JP¥1b
Mar 31 2020	n/a	n/a	-JP¥332m
Dec 31 2019	JP¥101m	JP¥40m	JP¥1b

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Chris sia ragionevole rispetto ad aziende di dimensioni simili nel mercato JP.

Compensazione vs guadagni: La retribuzione di Chris è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Chris Cargill (40 yo)

2.4yrs

Mandato

JP¥292,000,000

Compensazione

Mr. Christopher Cargill, also known as Chris, serves as Representative Executive Officer, President, Chief Executive Officer and Director at Nxera Pharma Co., Ltd. (formerly known as Sosei Group Corporatio...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Shinichi Tamura	Founder & Chairman of the Board	19.2yrs	JP¥332.00m	0.66% ¥ 1.0b
Christopher Cargill	Representative Executive Officer	2.4yrs	JP¥292.00m	0.046% ¥ 72.2m
Hironoshin Nomura	Executive Officer	2.4yrs	Nessun dato	0.0016% ¥ 2.4m
Toshihiro Maeda	Executive VP & COO	less than a year	Nessun dato	Nessun dato
Kieran Johnson	Executive Officer	2.4yrs	Nessun dato	0.0077% ¥ 12.0m
Kazuhiko Yoshizumi	Executive Officer	6.6yrs	Nessun dato	0.0093% ¥ 14.4m
Shinichiro Nishishita	VP of Investor Relations & Head of Regulatory Disclosures	no data	Nessun dato	Nessun dato
Stacey Southall	Associate Director & Head of Biophysics	no data	Nessun dato	Nessun dato
Candelle Chong	Executive Officer	1.4yrs	Nessun dato	0.0063% ¥ 9.9m
Satoshi Tanaka	Exe. Off.	1.1yrs	Nessun dato	Nessun dato
Patrick Branch	Head of Business Development for Japan and the APAC region	less than a year	Nessun dato	Nessun dato
Matthew Barnes	Hd. of Drug Disc. & UK R&D	2.4yrs	Nessun dato	0.0031% ¥ 4.8m

2.4yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di 4565 è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Shinichi Tamura	Founder & Chairman of the Board	19.2yrs	JP¥332.00m	0.66% ¥ 1.0b
Christopher Cargill	Representative Executive Officer	2.4yrs	JP¥292.00m	0.046% ¥ 72.2m
Malcolm Weir	Member of Scientific Advisory Board	less than a year	JP¥134.00m	Nessun dato
Rolf Kristian Berndtson Soderstrom	Independent External Director	4.4yrs	Nessun dato	0.016% ¥ 24.8m
Tomohiro Tohyama	Independent External Director	13.2yrs	Nessun dato	0.057% ¥ 88.7m
Noriaki Nagai	External Independent Director	5.4yrs	Nessun dato	0.038% ¥ 59.1m
Kuniaki Kaga	Independent External Director	6.2yrs	Nessun dato	0.040% ¥ 61.6m
David Roblin	Independent External Director	6.2yrs	Nessun dato	0.0073% ¥ 11.3m
Paul Leeson	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Peter Bernstein	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Richard Henderson	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Miwa Seki	External Independent Director	2.4yrs	Nessun dato	0.013% ¥ 19.5m

5.4yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 4565 sono considerati esperti (durata media dell'incarico 5.4 anni).

Nxera Pharma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

High number of new directors

Recent updates

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Nxera Pharma Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

Is Nxera Pharma (TSE:4565) A Risky Investment?

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease

Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Sosei Group Corporation to Report Q1, 2024 Results on May 09, 2024

Now 24% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

Now 21% overvalued after recent price rise

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

New minor risk - Shareholder dilution

Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea

Sosei Group Corporation to Report Fiscal Year 2023 Results on Feb 13, 2024

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Idorsia Pharmaceuticals Japan Ltd. Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the Approval of Daridorexant

Price target decreased by 9.0% to JP¥2,281

Consensus revenue estimates increase by 12%

Sosei Group Corporation to Report Q3, 2023 Results on Nov 10, 2023

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Second quarter 2023 earnings released: JP¥8.01 loss per share (vs JP¥17.95 loss in 2Q 2022)

Price target increased by 8.2% to JP¥2,443

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia

Now 38% undervalued after recent price drop

Consensus EPS estimates fall by 30%

New major risk - Share price stability

Price target decreased by 16% to JP¥2,957

Sosei Group Corporation to Report Q2, 2023 Results on Aug 04, 2023

Price target increased by 8.9% to JP¥3,500

Now 21% undervalued

Consensus EPS estimates increase by 30%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 39%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Sosei Group Corporation to Report Q3, 2022 Results on Nov 11, 2022

Price target increased to JP¥2,950

Second quarter 2022 earnings released: JP¥17.95 loss per share (vs JP¥14.11 loss in 2Q 2021)

Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development Under Multi-Program Collaboration with Neurocrine Biosciences

Consensus revenue estimates increase by 18%

Cancer Research UK and Sosei Heptares Signs Agreement to Advance Cancer Immunotherapy Candidate into Clinical Trials

Sosei Group Corporation to Report Q2, 2022 Results on Aug 10, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%

Price target decreased to JP¥2,600

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

Consensus revenue estimates increase to JP¥16.5b

Price target increased to JP¥2,767

Third quarter 2021 earnings released: EPS JP¥5.80 (vs JP¥5.94 in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥14.11 loss per share (vs JP¥17.76 loss in 2Q 2020)

High number of new directors

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven

Sosei Group Corporation Provides Update of Their Strategic Multi-Target Drug Discovery Collaboration with Pfizer

First quarter 2021 earnings released: JP¥14.28 loss per share (vs JP¥9.68 loss in 1Q 2020)

Full year 2020 earnings released: EPS JP¥18.78 (vs JP¥18.69 in FY 2019)